Standard BioTools Q4 rev $27M (+8.3% seq); FY22 rev $97.9M vs $130.6M; guides 2023 flat-to-mod growth

STANDARD BIOTOOLS INC.

2022-FY EPS reported -$2.43 revenue$97,948,000

Q4 2022 GAAP revenue $27.0M; core product/service rev $26.8M, up 8.3% sequentially.
Full year GAAP revenue $97.9M (down from $130.6M in 2021); core rev $94.5M vs $111.6M.
Q4 product margin GAAP 40.9% (+620 bps seq), non-GAAP 52.9% (+520 bps); opex down 16% seq to $32.3M.
2023 guidance: flat-to-moderate core rev growth; GAAP opex ~$118-123M (20% reduction); Q4 GAAP gross margin 52-55%.
Cash $165.8M at year-end; expects positive free cash flow by end of 2024; restructuring to cut >$30M opex annually.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

STANDARD BIOTOOLS INC. reported the fiscal year ended December 31, 2022 results: revenue $97.9 million. Guidance reaffirmed.

Period: the fiscal year ended December 31, 2022
Revenue: $97.9 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

GAAP revenues were $97.9 million compared to $130.6 million in 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

STANDARD BIOTOOLS INC. updated its 2023 guidance (initiated).

Period: 2023
Guidance: initiated
Result: guidance update

Exact text from the filing

For 2023, Standard BioTools expects flat-to-moderate growth in core product and service revenues relative to 2022 core product and service revenues of $94.5 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

STANDARD BIOTOOLS INC. reported the three months ended December 31, 2022 results: revenue $27.0 million. Guidance reaffirmed.

Period: the three months ended December 31, 2022
Revenue: $27.0 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Fourth quarter 2022 GAAP revenues were $27.0 million.

View on SEC.gov

Browse all earnings releases →

STANDARD BIOTOOLS INC. filing history →

Source: SEC EDGAR

accession 0000950142-23-000411

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.